Annual Report

Overview

The report describes a 10.0% NAV total return for the year ended 31 March 2026, ahead of the 1.8% benchmark. The company attributes performance to healthcare investing, with biotechnology representing a 31.8% absolute portfolio weight at year-end and pharmaceuticals 34.1%. Its ESG disclosure explains that OrbiMed published a TCFD-based report in September 2025 and uses SASB sector guidance in its research.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2026
Period: 1 April 2025 – 31 March 2026
Publication date: 4 June 2026
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services